Group 1 - Century Therapeutics reported quarterly earnings of $0.89 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.31 per share, and improving from a loss of $0.45 per share a year ago, resulting in an earnings surprise of 387.10% [1] - The company achieved revenues of $109.16 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 139.84%, compared to revenues of $0.86 million in the same quarter last year [2] - Century Therapeutics has outperformed consensus EPS estimates for four consecutive quarters and has topped consensus revenue estimates three times in the last four quarters [2] Group 2 - Despite the positive earnings report, Century Therapeutics shares have declined approximately 51.6% since the beginning of the year, contrasting with the S&P 500's gain of 0.2% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $10.29 million, and for the current fiscal year, it is -$1.10 on revenues of $73.35 million [7] Group 3 - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 26% of over 250 Zacks industries, suggesting a favorable outlook for companies within this sector [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates